Researchers for the ongoing 30-year Diabetes Prevention Program found out last week that the NIH canceled funding for the ...

Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions ...

Intercept Pharma’s obeticholic acid (OCA) – trying to become the first FDA-approved therapy for non-alcoholic steatohepatitis (NASH) – will come under scrutiny by FDA advisors before the ...

Intercept Pharma's hopes of getting its non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA) in the US may have taken another dive, after it flunked a phase 3 trial. Shares in the ...

Ocaliva (obeticholic acid) is a prescription drug that’s used to treat primary biliary cholangitis (PBC). Ocaliva comes as an oral tablet. Ocaliva is used to treat primary biliary cholangitis ...

Intercept Therapeutics’ efforts with FXR agonist Ocaliva (obeticholic acid) ended in disappointment when the US Food and Drug Administration (FDA) rejected the drug for MASH in 2023, forcing the ...

The FDA rejected Intercept’s drug, dubbed Ocaliva or obeticholic acid, for patients with MASH after raising concerns over the drug’s modest efficacy and range of safety problems. That 2023 ...

Therapeutic advancements have already begun to show promise. FXR agonists such as obeticholic acid (OCA) have demonstrated potential in reducing liver lipid accumulation and inflammation, though ...

New treatments, such as obeticholic acid, are being studied and have demonstrated the ability to reduce liver fat and inflammation.” Omega-3s: Consuming fish or Cod Liver Oil capsules regularly ...